- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Giredestrant Improves iDFS Compared With Endocrine Therapy in ER+, HER2– Breast Cancer
December 10th 2025, 7:53pm
San Antonio Breast Cancer Symposium
Giredestrant improved invasive disease-free survival vs endocrine therapy in ER-positive, HER2-negative, medium- and high-risk early breast cancer.
Adjuvant Aromatase Inhibition Is Associated With Improved DFS, TTDR in HR+/HER2+ Breast Cancer
December 10th 2025, 6:35pm
San Antonio Breast Cancer Symposium
Adjuvant AI therapy improved DFS and TTDR vs a SERM in patients with hormone receptor–positive, HER2-positive early breast cancer.
Dr Rimm on Conceptual Considerations Surrounding ADC Mechanisms in Breast Cancer
December 10th 2025, 4:30pm
San Antonio Breast Cancer Symposium
David Rimm, MD, PhD, discusses key conceptual considerations and discrepancies regarding the mechanisms of action of ADCs in breast cancer treatment.
Axi-Cel Is Safe and Effective in Real-World R/R Follicular Lymphoma
December 10th 2025, 1:00pm
ASH Annual Meeting and Exposition
Axi-cel led to durable responses and manageable safety in patients with relapsed/refractory follicular lymphoma.
Dr Kamdar on the Long-Term Efficacy of Liso-Cel in R/R LBCL
December 10th 2025, 2:10am
ASH Annual Meeting and Exposition
Manali Kamdar, MD, discusses the long-term efficacy findings with lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.
Decoding Developments in GVHD Management With Drs Salhotra and Negrin
December 9th 2025, 11:15pm
OncLive News Network: On Location at ASH 2025
Amandeep Salhotra, MD, and Robert Negrin, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in graft-vs-host disease presented during the 2025 ASH Annual Meeting & Exposition.
Pelabresib Plus Ruxolitinib Bests Ruxolitinib Monotherapy in JAK Inhibitor-Naive Myelofibrosis
December 9th 2025, 10:58pm
ASH Annual Meeting and Exposition
Pelabresib plus ruxolitinib improved primary and secondary efficacy end points vs ruxolitinib alone in JAK inhibitor-naive myelofibrosis.
Dr Vincent-Salomon on Persisting Gaps in Clinical Interpretation of Invasive Lobular Carcinoma
December 9th 2025, 10:55pm
San Antonio Breast Cancer Symposium
Anne Vincent-Salomon, PR, MD, PhD, HDR, highlights persistent gaps that continue to challenge reproducibility and clinical interpretation in the diagnostic classification of invasive lobular carcinoma.
Axatilimab Shows Long-Term Safety and Clinical Benefit in Pretreated Chronic GVHD
December 9th 2025, 10:07pm
ASH Annual Meeting and Exposition
Long-term follow-up data from the AGAVE-201 trial showed that safety and survival outcomes with axatilimab were maintained in patients with chronic GVHD.
Early Data Show Deep MRD-Negative Responses, CAR T-Cell Persistence With KLN-1010 in R/R Myeloma
December 9th 2025, 9:02pm
ASH Annual Meeting and Exposition
The in vivo, BCMA-directed CAR T-cell therapy produced initial MRD-negative responses and persistent CAR T-cell expansion in 4 patients with relapsed/refractory myeloma.
BCMA/CD19-Directed CAR T-Cell Therapy Yields 100% ORR in Newly Diagnosed Myeloma
December 9th 2025, 8:42pm
ASH Annual Meeting and Exposition
GC012F/AZD0120 produced responses in high-risk, transplant-eligible multiple myeloma, as well as transplant-ineligible, newly diagnosed disease.
Limited-Duration Teclistamab Drives Durable Responses in Relapsed/Refractory Myeloma
December 9th 2025, 7:22pm
ASH Annual Meeting and Exposition
Early teclistamab discontinuation after deep response showed PFS comparable to continuous therapy in relapsed/refractory myeloma in the LimiTEC trial.
Teclistamab Plus Daratumumab Yields OS, PFS Benefit in R/R Multiple Myeloma
December 9th 2025, 4:13pm
ASH Annual Meeting and Exposition
Teclistamab/daratumumab improved survival outcomes and led to deep MRD-negative responses vs daratumumab-based regimens in relapsed/refractory myeloma.
Pirtobrutinib Yields Improved Efficacy Over BR in First-Line CLL/SLL
December 9th 2025, 3:30pm
ASH Annual Meeting and Exposition
Pitrobrutinib monotherapy showed significant efficacy improvements in first-line CLL/SLL compared with BR treatments.
Zanubrutinib Plus Venetoclax Displays Long-Term PFS Benefit in Untreated CLL/SLL
December 9th 2025, 3:13pm
ASH Annual Meeting and Exposition
Zanubrutinib plus venetoclax maintained a 36-month PFS rate of 87% (95% CI, 78.6%–92.4%) in treatment-naive CLL/SLL.
GLPG5101 Produces Responses With Manageable Safety in R/R NHL, MCL
December 9th 2025, 2:47pm
ASH Annual Meeting and Exposition
GLPG5101 produced responses and had a manageable safety profile in relapsed/refractory non-Hodgkin lymphoma, including mantle cell lymphoma.
MK-1045 Therapy Proves Active, Safe With Dose Modification in Relapsed/Refractory ALL
December 9th 2025, 2:45pm
ASH Annual Meeting and Exposition
The safety profile associated with MK-1045 administration was manageable with dose interruption and standard medical care.
SEQUOIA Long-Term Data Continue to Support Zanubrutinib in Treatment-Naive CLL/SLL
December 9th 2025, 2:05pm
ASH Annual Meeting and Exposition
Zanubrutinib shows sustained 6-year efficacy and safety in treatment-naive CLL/SLL, outperforming BR with durable PFS and high response rates.
Dr Leslie on Epcoritamab Plus Lenalidomide and Rituximab in Follicular Lymphoma
December 9th 2025, 2:55am
ASH Annual Meeting and Exposition
Lori A. Leslie, MD, discusses 3-year efficacy findings with epcoritamab plus rituximab and lenalidomide in previously untreated follicular lymphoma.
Dr Haddad on the Efficacy of Asciminib in Newly Diagnosed CML
December 9th 2025, 2:45am
ASH Annual Meeting and Exposition
Fadi Haddad, MD, discusses the efficacy of asciminib in patients with newly diagnosed chronic myeloid leukemia as seen in a phase 2 trial.